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154 The Journal of Thoracic and Cardbjective: Some reports have documented a higher early mortality with the use of extended
riteria donors in lung transplantation. None have evaluated how outcomes compare with the
se of these organs for single and bilateral transplantation or whether this practice results in
higher incidence of early bronchiolitis obliterans syndrome.
ethods: We performed a retrospective review of case notes, intensive therapy unit
atabase, and donor details. Between January 1, 2000, and December 31, 2004, 201
atients underwent lung or heart-lung transplantation.
esults: Eighty-three (41.3%) patients received organs deemed marginal on the
asis of at least one of the following criteria: donor age greater than 55 years,
uration of ventilation greater than 5 days, purulent secretions or inflammation at
ronchoscopy, smoking of 20 or more cigarettes per day, abnormality on chest
oentgenogram, or PO2/fraction of inspired oxygen ratio of less than 300 mm Hg
mmediately before donor organ procurement. Recipients of marginal lungs had a
igher incidence of severe (grade 3) primary graft dysfunction (43.9% vs 27.4%, P
.015) and 90-day organ-specific mortality (15.7% vs 5.1%, P  .012). Bilateral
ransplantation carried a significantly higher 30-day mortality if performed with
arginal organs (17.0% vs 2.7% with standard donor organs, P  .005). Thirty-day
ortality was not significantly different for the transplantation of single marginal or
tandard donor lungs. Cumulative survival and survival free of bronchiolitis oblit-
rans syndrome was not affected by marginal donor status.
onclusion: Transplantation of extended criteria donor lungs leads to a higher incidence of
rimary graft dysfunction. Bilateral transplantation with these organs seems to confer less
eserve, resulting in a higher early mortality rate. Medium-term functional outcome is,
owever, not adversely affected by the relaxation of donor criteria.
t least 14% of patients on the waiting list for lung transplantation in the
United Kingdom continue to die each year. A further 2% of patients are
removed from the list because of deterioration in their clinical cond1
n the subgroup of patients with fibrotic lung disease, up to 40% die before
ransplantation in many series.2,3 Donor organ shortage thus remains one of 
oremost causes of death for patients with end-stage lung disease eligible for
ransplantation. Several methods of expanding the current donor pool have been
uggested, with the relaxation of previously strict donor criteria and use of donor
rgans previously deemed unsuitable or “marginal” being used in many centers. Opti-
ization of donor management has also received much interest because this has resulted
n higher procurement rates.4 Despite these measures, only 18% of brainstem-d
rgan donors in the United Kingdom have lungs suitable for transplantation.1
Several authors have evaluated the use of marginal donors in their own centers,
ith conflicting reports documenting either identical outcomes to those with stan-
ard donors or, in some cases, greater risk of early mortality.5,6 To date, donor data
iovascular Surgery ● May 2006
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TXre only collected by individual centers, and no centralized
atabase exists. As a result, there are no validated criteria
or designating donors as marginal, and criteria used have
iffered from center to center. This has undoubtedly af-
ected outcome analysis. Some have questioned how the use
f marginal organs for higher-risk recipients affects trans-
lantation outcome as a whole.5 None have evaluated spe-
ifically how outcomes differ in single lung transplantation
SLT) versus bilateral lung transplantation (BLT) with mar-
inal organs. Published views support the use of marginal
rgans for BLT, a practice that reflects opinion and not an
vidence base.
These factors bear an important influence on decision
aking in transplantation, namely which recipients are suit-
ble for marginal lung allocation without conferring an unac-
eptable survival disadvantage. With lung transplantation
mparting disparate survival benefits to patients with differ-
nt diagnoses, the appropriate allocation of organs from
arginal donors should be made with concrete outcome
ata to support it. In an attempt to answer some of these
uestions, we retrospectively collected patient and donor
haracteristics, as well as outcome data, for all lung trans-
lantations performed at our center over a 5-year period and
nvestigated associations between marginal donor charac-
eristics and several measures of outcome.
atients and Methods
ata for all adult (age 16 years) lung and heart-lung transplant
ecipients at the Freeman Hospital during the period from January
, 2000, to December 31, 2004, were collected retrospectively by
eans of review of clinical notes, the intensive care database, and
onor information sheets.
arginal Donors
rgan assessment at the time of procurement included review of
vailable chest roentgenograms (CXR), flexible bronchoscopy, in-
pection and palpation of the thoracic cavity and lungs, and measure-
ent of differential pulmonary vein gasses. Additional factors as-
essed in identifying marginal donors included age, smoking history,
nd duration of ventilation. Donors were considered marginal if they
et any of the following criteria: age greater than 55 years, current
moking of 20 or more cigarettes per day, duration of ventilation of
Abbreviations and Acronyms
BLT  bilateral lung transplantation
BOS  bronchiolitis obliterans syndrome
CPB  cardiopulmonary bypass
CXR chest roentgenogram
FIO2  fraction of inspired oxygen
ITU  intensive therapy unit
PGD primary graft dysfunction
SLT  single lung transplantationonger than 5 days, radiographic infiltrates in the lung to be trans- g
The Journal of Thoraciclanted, purulent secretions or inflammation at bronchoscopy, arterial
O2 of less than 40 kPa (300 mm Hg) on 100% inspired oxygen, and
cm H2O of positive end-expiratory pressure at last measurement
efore donor pneumonectomy.
ung Allocation and Transplantation
ung allocation in the United Kingdom is based on zones. If no
uitable recipient exists within the zonal transplant center, the
rgan or organs are offered to extraregional centers through the
ational organ allocation network. Offers are made to centers on a
equential basis, determined by when they last accepted an organ
rom the national pool. Significant autonomy exists within the
enters to allocate offered organs to an appropriate recipient on the
asis of blood group, size match, urgency, diagnosis, and time on
he waiting list.
As of April 2001, we have used a single flush technique with
erfadex (Vitrolife Göteborg, Sweden) and side-table retrograde
ush with the same solution for organ preservation. Other zonal
enters have used alternative preservation methods, including
uro-Collins or Papworth solutions or core cooling, during the
tudy period. Lung transplantation is performed with single lung
entilation or cardiopulmonary bypass (CPB) where indicated in
ingle lungs. CPB is used as a routine for all bilateral sequential
ransplants. Reperfusion is performed at controlled pressure with
naltered blood.
arly and Late Graft Dysfunction
rimary graft dysfunction (PGD) scoring was performed retro-
pectively on the basis of gas exchange data derived from the
ntensive care notes and radiologist reports of postoperative CXRs.
coring was performed according to the International Society for
eart and Lung Transplantation working classification for PGD as
ollows7: grade 0, no abnormality on CXR and PO2/fraction of
nspired oxygen (FIO2) ratio greater than 300 mm Hg; grade 1,
nfiltrates on CXR consistent with reimplantation edema and PO2/
IO2 ratio greater than 300 mm Hg; grade 2, CXR infiltrates and
O2/FIO2 ratio less than 300 mm Hg and greater than 200 mm Hg;
nd grade 3, CXR infiltrates and PO2/FIO2 ratio less than 200 mm
g. PGD scores were calculated for values at arrival in the
ntensive care unit and 24, 48, and 72 hours after transplantation.
aximum grade of PGD attained during the first 72 hours after
ransplantation was used for analysis. Alveolar-arterial oxygen
radient was calculated by using the alveolar gas equation at
rrival in the intensive care unit and 24 hours later.
Bronchiolitis obliterans syndrome (BOS) was defined accord-
ng to International Society for Heart and Lung Transplantation
uidelines.8 Grade 1 BOS (decrease in forced expiratory volum
second of more than 20% from baseline value) was used as onset
f BOS, and early onset of BOS was defined as onset within 1 year
f transplantation.
tatistical Considerations
nless otherwise stated, continuous data are presented as means
tandard deviation and analyzed by using a 2-sample t test. Vari-
bles with large standard deviations relative to the mean indicating
skewed distribution (eg, duration of ventilation and intensive
are unit stay) were analyzed with the Mann-Whitney test. Cate-
oric data are presented as counts followed by percentages in
and Cardiovascular Surgery ● Volume 131, Number 5 1155
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1
TXarentheses and analyzed by using the 2 test. Categoric survival
utcomes were 30- and 90-day mortality and organ-specific mor-
ality at 90 days. Cumulative survival and freedom from BOS were
alculated by using the Kaplan-Meier method, and groups were
ompared by using the log-rank test. All hypothesis tests used a
% significance level. Statistical analysis was performed with
PSS version 12.0.1 software.
esults
n the 5-year period studied, 201 lung and heart-lung trans-
lantations were performed. Of these, 62 (30.8%) were
LTs, 122 (60.7%) were BLTs, and 17 (8.5%) were heart-
ung transplantations. The most frequent recipient diagnosis
as suppurative lung disease (84 [41.8%]), whereas ob-
tructive lung disease (69 [34.5%]) and fibrotic lung disease
27 [13.5%]) accounted for most of the other diagnoses.
ecipient demographics are listed in Table 1. Eighty-th
41.3%) of the donors met at least one marginal criterion. Of
hese, 58 (28.9%) met 1 criterion, 19 (9.5%) met 2 criteria,
nd 6 (3.0%) met 3 criteria. Donor demographics are listed
n Table 2.
ABLE 2. Donor demographics
Donor demographics N  201
Age, y 36.7 13.7
Male sex 94 (46.8%)
Cause of death
Cerebrovascular event 118 (58.7%)
Head injury 56 (27.9%)
Infective 12 (6.0%)
Neoplastic 4 (2.0%)
Other 11 (5.5%)
Marginal criteria
Age 55 y 17 (8.5%)
Ventilated 5 days 19 (9.5%)
Smoking 20/d 32 (15.9%)
CXR infiltrates 21 (10.4%)
Abnormal bronchoscopy 14 (7.0%)
PO2 300 mm Hg 11 (5.5%)
Donors meeting 1 or more criteria 83 (41.3%)
ABLE 1. Recipient demographics
Recipient demographics N  201
Age, y 39.99 14.1
Male sex 95 (47.3%)
Diagnosis
Suppurative 84 (42.0%)
Obstructive 69 (34.5%)
Fibrotic 27 (13.5%)
PPH 10 (5.0%)
Other 10 (5.0%)
PH, Primary pulmonary hypertension.2XR, Chest roentgenogram.
156 The Journal of Thoracic and Cardiovascular Surgery ● Margan Allocation
n the 201 lung and heart-lung transplantations analyzed,
roportionally more SLTs were performed with marginal
rgans (32 [51.6%]). Bilateral transplantations were per-
ormed with marginal organs in 51 (36.7%) patients (P 
47). The allocation of standard organs favored patients in
he primary pulmonary hypertension and suppurative dis-
ase (predominantly cystic fibrosis) subgroups, whereas
lightly fewer patients with obstructive lung disease and
brotic lung disease received standard donor lungs (P 
36, Figure 1). Recipients of lungs from marginal do
ad a higher mean age (43.4  14 vs 37.6  13.8 years,
 .004).
ostoperative Graft Function
schemic time was 317  66 minutes for the group as a
hole and not statistically different for those receiving
arginal or standard lungs (319  65 and 316  67
inutes, respectively; P  .76). Severe (grade 3) PGD
ccurred in 68 (34.2%) of all transplantations performed.
ifferential outcomes for recipients receiving standard ver-
us marginal donor lungs are listed in Table 3. On in
ion of the differential outcome data at various durations of
schemic time, those longer than 405 minutes led to higher
ates of grade 3 PGD in recipients of marginal lungs (83.3%
s 40.8%, P  0.043). In recipients of standard lungs, this
nfluence of prolonged ischemic time was not observed
30.0% vs 27.1% grade 3 PGD, P  0.844).
Duration of positive pressure ventilation (median, 29 vs
igure 1. Allocation of marginal organs: percentage of patients in
ach diagnostic subgroup receiving organs from marginal donors.
PH, Primary pulmonary hypertension.9 hours; 95% confidence interval for difference, 7.0 to
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TX.0 hours; P  .76) and intensive therapy unit (ITU) stay
median, 3 vs 2 days; 95% confidence interval for differ-
nce, 1.0 to 1.0 days; P  .93) were not significantly
ifferent for marginal and standard donor lungs. Thirty-day
ortality for the entire cohort was 11.4% (n 23), whereas
0-day mortality was 16.9% (n  34). As demonstrated in
able 3, 30- and 90-day mortalities were not significa
ifferent among recipients of standard and marginal donor
ungs. Organ-specific mortality at 90 days (respiratory fail-
re or multiorgan failure with severe PGD) was, however,
ignificantly higher in recipients of marginal lungs (13
15.7%] compared with 6 [5.1%] in the standard donor
roup, Table 3).
ifferential Outcome
LT carried a significantly higher 30-day mortality than
LT (12 [19.4%] vs 10 [8.2%], P  .033). After heart-lung
ransplantation, the 30-day mortality was 5.7%. In the 62
ecipients of a single lung transplant, 30-day mortality did
ot differ significantly between those receiving marginal
nd standard organs (4/32 [12.5%] vs 8/30 [26.7%], P 
ABLE 3. Outcomes in recipients of standard donor lungs
ompared with marginal donor lungs
utcomes Standard donor Marginal donor P value
rade 3 PGD 32 (27.4%) 36 (43.9%) .015
ean Aa gradient
at 24 h
115 80 mm Hg 148 118 mm Hg .021
edian duration
of ventilation
29 h 29 h .76
edian ITU stay 2 d 3 d .93
0-d mortality 10 (8.5%) 13 (15.7%) .12
0-d mortality 15 (12.7%) 19 (22.9%) .058
rgan-specific
mortality (90 d)
6 (5.1%) 13 (15.7%) .012
OS at 1 y 13 (11%) 4 (4.8%) .12
GD, Primary graft dysfunction; Aa gradient, alveolar-arterial oxygen gradient;
TU, intensive therapy unit; BOS, bronchiolitis obliterans syndrome.The Journal of Thoracic158). In recipients of BLTs, however, the use of marginal
onor organs significantly affected 30-day mortality. Recip-
ents of bilateral marginal donor lungs had an unexpectedly
igh 30-day mortality of 17.0% (8/47), whereas the 30-day
ortality was low (2.7% [2/75]) in recipients of 2 standard
ungs (P  .005, Figure 2). At 90 days, this differenc
ortality rates remained statistically significant for patients
ndergoing BLT (P  .008) and nonsignificant for patients
ndergoing SLT (P  .47).
Thirty- and 90-day mortality rates were 18.5% and
9.6% for fibrotic lung disease, 15.9% and 23.2% for ob-
tructive lung disease, and 7.1% and 9.5% for suppurative
ung disease, respectively. SLT for obstructive lung disease
arried a statistically nonsignificant tendency for greater
isk of 30-day mortality (21.4%) than sequential lung trans-
lantation for the same indication (4.0%, P  .053). The
ize of the cohort undergoing transplantation for fibrotic
ung disease also prevented meaningful statistical analysis.
hen outcome of marginal organ use was analyzed for
ifferent diagnostic subgroups, only those undergoing
ransplantation for suppurative lung disease had signifi-
ant differences in outcome. Because of the obligatory
se of BLT in this group, 30-day mortality was similarly
igh (17.2%) for those receiving marginal organs and
ery low (1.8%) for recipients of standard organs (P 
009).
Survival was not statistically different for all-cause mor-
ality (P  .28, log-rank test; Figure 3) in the 2 gro
imilarly, organ-specific mortality was not statistically sig-
ificantly different for standard and marginal lungs (P 
23, log-rank test). The incidence of early-onset BOS
within 1 year of transplantation) was not statistically dif-
erent for the 2 groups, at 11.0% in recipients of standard
onor organs and 4.8% in recipients of marginal lungs (P
12). BOS-free survival was also calculated by using the
aplan-Meier method and was not statistically significantly
ifferent between marginal and standard transplants (P 
85, log-rank test; Figure 4).
Figure 2. Thirty-day mortality with marginal
and standard donors in single and bilateral
transplantation.and Cardiovascular Surgery ● Volume 131, Number 5 1157
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1
TXiscussion
ince the first report of successful relaxation of donor
riteria with acceptable outcome by Kron and colleagu9
everal centers have reported encouraging results in this
egard. In the absence of a validated set of criteria for
efining donors as marginal, the definition of the marginal/
xtended donor has varied, making comparison between
hese reports difficult. In the largest series to date, Gabbay
nd associates4 reported 140 transplants from 112 dono
ith 64 (57%) not meeting all criteria for standard lung
onors. Their marginal donors included 20 (31%) patients
ith low PO2/FIO2 ratios at referral, which improved to
cceptable levels with manipulation. They also used a large
umber (39) of organs with radiographic infiltrates and 24
onor lungs with infection, as defined by purulent secretions
r Gram staining. These organs were accepted if ischemic
ime would not be extended (beyond 6 hours); the recipient
as unlikely to undergo transplantation otherwise and re-
uired BLT. SLT was performed only where clear unilateral
onor lung dysfunction existed. They found no significant
ifference in gas exchange, ITU stay, and early mortality
ith the use of these lungs. Straznicka and colleagu10
eported no difference in outcome with the use of marginal
rgans that included a large group of more than 51% in
hom a previous low PO2/FIO2 ratio or CXR abnormality
ad been corrected by means of donor management. They
lso showed no difference in survival with the use of stan-
igure 3. Cumulative survival (all-cause mortality) for recipients
f standard versus marginal donor lungs (in days). P  .28,
og-rank test.ard or extended criteria lungs when recipient diagnosis was p
158 The Journal of Thoracic and Cardiovascular Surgery ● Mantered into a Cox proportional hazards model. The Toronto
roup was the first to document a higher early mortality
ith the use of marginal donor organs.5 They especially
autioned against the use of marginal organs in high-risk
ecipients. They demonstrated a higher mortality (22.2%)
hen these organs were used for transplantation in patients
f advanced age or with Burkholderia cepacia colonization
efore transplantation. Our experience has confirmed their
ndings, showing a higher early organ-specific mortality
ith the use of marginal donor lungs.
Sundaresan and colleagues11 documented no differenc
n early outcome between recipients of standard and mar-
inal organs but found that CPB was required more fre-
uently for implantation of the second lung in BLT with
arginal organs (20%). They postulated that some revers-
ble lung dysfunction might be better tolerated by patients
ith emphysema and avoided the use of marginal organs in
atients with fibrotic lung disease. Bhorade and coworke12
ound no difference in hospital survival but demonstrated a
tatistically nonsignificant difference in spirometry of single
arginal lung recipients. They therefore cautioned against
he use of single lungs from extended donors. In our cohort,
ecipients of bilateral marginal lungs had a significantly
igher 30-day mortality than those receiving 2 lungs from a
tandard donor. The criteria used to define our cohort might
lay a significant role in this finding because a higher
roportion of our patients failed at least one criterion af-
ecting the function of both lungs (ie, age, smoking, dura-
ion of ventilation, and low total PO2/FIO2 ratio before donor
igure 4. Cumulative bronchiolitis obliterans syndrome (BOS)–
ree survival (in days). P  .85, log-rank test.neumonectomy).13 We postulated that current heavy
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TXmoking would have more effect on early graft function
han a long smoking history. This was confirmed by the
nding of a significantly higher alveolar-arterial oxygen
radient 24 hours after transplantation and longer ITU stay
n those receiving lungs from heavy smokers (179  111
mHg vs 122  95 mmHg, P  .01, and median ITU stay
f 5 vs 2 days). Although the method of preservation has
iffered from center to center and over time within our
tudy population, a subset analysis revealed a similar dis-
ribution of known preservation techniques among marginal
nd standard donor lungs. The incidence of PGD was
lightly higher for non-Perfadex preservation methods, but
his difference did not reach statistical significance (results
ot shown). Our routine use of CPB for BLTs might play a
ole in aggravating PGD in the marginal lungs. Although
revious studies have shown no difference in outcome with
he use of CPB for BLT,14 we postulate that marginal don
ungs might be more vulnerable to the injurious effects of
PB. We continue to support the use of routine CPB for all
LTs because of the absolute hemodynamic stability and
ontrolled pressure reperfusion it affords. We are, however,
nvestigating the amelioration of injury caused by bypass-
ctivated leukocytes through depletion or pharmacologic
eans to minimize reperfusion-related injury.
The finding of greater early mortality with BLT with
arginal lungs has significant implications for the alloca-
ion of donor organs. In the only subgroup in which BLT is
andatory (ie, those with suppurative lung disease), the use
f marginal donor lungs results in a significant increase in
arly mortality. One possible solution might be to allocate
circumstances allowing) these organs predominantly to
hose with obstructive disease where either single or bilat-
ral transplantation can be performed. Other series have
hown no difference in early mortality with SLT or BLT for
bstructive disease15 but some improvement in late functi
ith BLT.16 We prefer to allocate only organs deemed n
deal to those with cystic fibrosis and pulmonary hyperten-
ion. Because of the high waiting list mortality2,17 and
bsence of proved survival benefit with BLT,18 single mar-
inal lungs will, of necessity, continue to be used in those
ith fibrotic lung disease.
In this analysis we have demonstrated a higher rate of
GD and early lung-specific mortality with the use of mar-
inal donor lungs. In keeping with our previous findings, the
igher incidence of early allograft damage did not result in
higher incidence of early-onset BOS or poorer BOS-free
urvival.19 Longer follow-up will be needed to exclud
igher lifetime risk of BOS. Our finding of significantly
igher 30-day mortality with the use of marginal donor
ungs for BLT has significant implications for allocation
trategy. The obvious factor that might account in part for
his finding is our routine use of CPB for bilateral sequential
ransplantations. This might aggravate ischemia-reperfusion
The Journal of Thoracicnjury in marginal lungs with limited reserve and influence
irect comparison between the groups. Notably, other cen-
ers have documented a higher necessity for the use of CPB
hen marginal lungs are implanted sequentially.11 It would
onetheless be interesting to see whether our findings would
e duplicated in centers in which BLT is performed rou-
inely without the use of CPB.
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